Anika Therapeutics (NASDAQ: ANIK) shareholders back equity plans and director slate
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Anika Therapeutics, Inc. reported the results of its 2026 Annual Meeting of Stockholders and approvals of equity compensation plan amendments. Stockholders approved a revised omnibus incentive plan that increases the common stock reserved under the plan by 350,000 shares to 6,110,000 shares and allows all of these shares to be granted as incentive stock options. They also approved an amendment to the 2021 Employee Stock Purchase Plan, doubling its share reserve from 200,000 to 400,000 shares.
All three Class III director nominees were elected to terms ending at the 2029 annual meeting, the advisory say-on-pay vote passed, and Deloitte & Touche LLP was ratified as independent auditor for the fiscal year ending December 31, 2026. At the meeting, 11,195,667 of 13,305,624 eligible shares were represented, reflecting 84.14% of the voting power.
Positive
- None.
Negative
- None.
8-K Event Classification
3 items: 5.02, 5.07, 9.01
3 items
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 5.07
Submission of Matters to a Vote of Security Holders
Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Incentive plan increase: 350,000 shares
Total incentive plan reserve: 6,110,000 shares
ESPP reserve increase: 200,000 shares
+5 more
8 metrics
Incentive plan increase
350,000 shares
Additional common shares reserved under revised omnibus incentive plan
Total incentive plan reserve
6,110,000 shares
Common shares reserved under revised omnibus incentive plan
ESPP reserve increase
200,000 shares
Increase in 2021 Employee Stock Purchase Plan from 200,000 to 400,000 shares
ESPP total reserve
400,000 shares
Common shares reserved under amended 2021 Employee Stock Purchase Plan
Shares entitled to vote
13,305,624 shares
Common stock entitled to vote at 2026 Annual Meeting
Shares represented
11,195,667 shares
Shares present in person or by proxy, 84.14% of voting power
Auditor ratification votes for
11,136,590 votes
Votes in favor of ratifying Deloitte & Touche LLP for 2026
Say-on-pay votes for
8,268,676 votes
Votes supporting executive compensation on an advisory basis
Key Terms
Omnibus Incentive Plan, incentive stock options, Employee Stock Purchase Plan, non-binding, advisory basis, +1 more
5 terms
Omnibus Incentive Plan financial
"Sixth Amendment and Restatement of the Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan"
An omnibus incentive plan is a single, flexible program a company uses to give employees and executives different types of pay tied to performance — for example stock options, restricted shares, cash bonuses and other awards — all governed by one set of rules. It matters to investors because it determines how many new shares may be created, how leaders are motivated and how much the company will spend on compensation over time; think of it as a master toolbox that affects both costs and the total share supply.
incentive stock options financial
"All 6,110,000 shares authorized under the Revised Seventh Amended Plan may be granted as incentive stock options"
Incentive stock options are a type of employee stock option that gives eligible workers the right to buy company shares at a fixed price later on, often below future market value. They matter to investors because they align employee incentives with company performance, can dilute existing ownership when exercised, and create potential tax advantages for option holders if certain holding-time rules are met — think of them as a coupon to buy stock at today’s price with extra tax rules attached.
Employee Stock Purchase Plan financial
"amendment to the Anika Therapeutics, Inc. 2021 Employee Stock Purchase Plan, or the ESPP"
An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.
non-binding, advisory basis regulatory
"Stockholders voted, on a non-binding, advisory basis, to approve the compensation paid"
A non-binding, advisory basis means a recommendation or decision that carries no legal force and does not obligate the parties to act; it’s similar to a friendly suggestion rather than a signed promise. For investors, this matters because such guidance can influence market expectations and management plans but offers no guarantee of follow-through, so investors should treat it as informative input rather than a firm commitment.
broker non-votes regulatory
"For | | Against | | Abstain | | Broker Non-Votes 8,268,676 | | 1,093,946 | | 31,179 | | 1,801,866"
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
FAQ
What did Anika Therapeutics (ANIK) stockholders approve at the 2026 Annual Meeting?
Stockholders approved director elections, a revised omnibus incentive plan, an amendment to the 2021 Employee Stock Purchase Plan, executive compensation on an advisory basis, and ratified Deloitte & Touche LLP as independent auditor for the fiscal year ending December 31, 2026.
How did Anika Therapeutics (ANIK) change its 2017 Omnibus Incentive Plan?
The revised plan increased the number of common shares reserved from 5,760,000 to 6,110,000, an addition of 350,000 shares. All 6,110,000 shares may be granted as incentive stock options under Section 422 of the Internal Revenue Code.
What changes were made to Anika Therapeutics (ANIK) 2021 Employee Stock Purchase Plan?
The amendment doubled the share reserve under the 2021 Employee Stock Purchase Plan from 200,000 to 400,000 shares. No other provisions of the ESPP were changed, and the amended plan was approved by stockholders at the 2026 Annual Meeting.
Were Anika Therapeutics (ANIK) executive compensation practices approved by stockholders?
Yes. On a non-binding advisory basis, 8,268,676 votes were cast for approving named executive officer compensation, 1,093,946 against, and 31,179 abstentions, with 1,801,866 broker non-votes recorded for this say-on-pay proposal.
Which directors were elected at Anika Therapeutics (ANIK) 2026 Annual Meeting?
Stockholders elected Gary P. Fischetti, John B. Henneman, III, and Stephen D. Griffin as Class III directors. Each will serve until the 2029 Annual Meeting of Stockholders and until a successor is duly elected and qualified or earlier resignation or removal.